For example, Hata and coworkers have recently shown that acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to anti-EGFR therapy can occur through the genetic evolution of initially EGFRT790M-negative drug-tolerant cells (Hata et al. 2016). This evidence concerns the gene EGFR and non-small cell lung carcinoma.